Torrent Pharmaceuticals Limited (TORNTPHARM) — Financial Results | 28 July 2025(3 announcements)

Torrent Pharmaceuticals reported consolidated revenue of ₹1,811 crores for Q1 FY2025-26, up 11% year-on-year, driven by growth in domestic (19%), US (9%), Germany (11%), and Brazil (10%) markets. International revenues rose 10% to ₹533 crores, while total revenue reached ₹3,178 crores. The filing confirms unaudited results for the quarter ended June 30, 2025.

Torrent Pharmaceuticals reported a 69.9% YoY revenue increase to ₹87.22 crores for Q1 FY2025, driven by strong domestic sales, while net profit rose 32% to ₹22.15 crores on improved margins and cost control, reflecting robust operational performance.

Torrent Pharmaceuticals reported consolidated revenue of ₹3,178 crores for Q1 FY26, up 11% YoY, driven by strong domestic and international performance. Net profit rose 20% to ₹548 crores, supported by operational efficiency and strategic progress on the JB Pharma acquisition. The company finalized a proposed 46.39% stake purchase at ₹1,600 per share, with a total consideration of ₹11,917 crores and a mandatory open offer for an additional 26%. The audit committee approved the results on July 28, 2025, following an unqualified opinion from 8 SR & Co. LLP. Revenue growth was led by India (11%), Brazil (11%), Germany (9%), and the U.S. (9%).